Skip to main content
SpringerLink
Log in

No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia

  • Drug Interactions
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: The effect of citalopram on steady-state plasma concentrations of the newer antipsychotics clozapine and risperidone was studied in 15 schizophrenic patients with residual negative symptoms.

Methods: Eight patients stabilised on clozapine therapy (200 to 400 mg/day) and seven on risperidone (4 to 6 mg/day) received additional citalopram (40 mg/day) for 8 consecutive weeks.

Results: There were no significant changes in plasma concentrations of clozapine, risperidone and their active metabolites during the study period, suggesting that citalopram does not affect their metabolism. An improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, was observed in two patients in each group and the drug combination was well tolerated.

Conclusion: While controlled studies are needed to evaluate the clinical benefits of citalopram in chronic schizophrenia, our findings indicate that citalopram may be added to the therapy of patients on maintenance treatment with clozapine or risperidone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649–57

    PubMed  CAS  Google Scholar 

  2. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study. Biol Psychiatry 1992; 31: 698–704

    Article  PubMed  CAS  Google Scholar 

  3. Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281–5

    Article  PubMed  CAS  Google Scholar 

  4. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11Suppl. 5: 31–61

    Article  PubMed  Google Scholar 

  5. Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997; 33: 454–71

    Article  PubMed  CAS  Google Scholar 

  6. Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200–23

    Article  CAS  Google Scholar 

  7. Goff D, Midha K, Brotman A, et al. Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 1991; 148: 790–2

    PubMed  CAS  Google Scholar 

  8. Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35: 335–9

    PubMed  CAS  Google Scholar 

  9. Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates CNS side effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334–47

    Article  PubMed  CAS  Google Scholar 

  10. Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25: 24–32

    PubMed  CAS  Google Scholar 

  11. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177–87

    Article  PubMed  CAS  Google Scholar 

  12. Hiemke C, Weighmann H, Dahmen N, et al. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81

    Article  PubMed  CAS  Google Scholar 

  13. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74

    Article  PubMed  CAS  Google Scholar 

  14. Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5

    PubMed  CAS  Google Scholar 

  15. Centorrino F, Baldessarini RJ, Frankenburg F, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153: 820–2

    PubMed  CAS  Google Scholar 

  16. Spina E, Avenoso A, Facciolà G, et al. Effect of fluoxetine on plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13: 141–5

    Article  PubMed  CAS  Google Scholar 

  17. Taylor D, Ellison Z, Shaw LE, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998; 13: 19–21

    Article  PubMed  CAS  Google Scholar 

  18. Andreasen NC. Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa, 1983

  19. Avenoso A, Facciolà G, Campo GM, et al. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1998; 714: 299–308

    Article  CAS  Google Scholar 

  20. Olesen OV, Linnet K. Simplified high-performance liquid Chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Appl 1997; 698: 209–16

    Article  CAS  Google Scholar 

  21. Oyehaug E, Ostensen ET, Salvesen B. High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr B Biomed Appl 1984; 308: 199–208

    Article  CAS  Google Scholar 

  22. Andreasen NC. Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa, 1984

    Google Scholar 

  23. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand 1970; 212 Suppl.: 11–9

    Article  CAS  Google Scholar 

  24. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 1994; 38: 471–3

    Article  PubMed  CAS  Google Scholar 

  25. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25: 1379–82

    PubMed  CAS  Google Scholar 

  26. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–44

    Article  PubMed  CAS  Google Scholar 

  27. Brosen K, Skielbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4

    Article  PubMed  CAS  Google Scholar 

  28. Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151–9

    Article  PubMed  CAS  Google Scholar 

  29. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver. Br J Clin Pharmacol 1992; 34: 262–5

    Article  PubMed  CAS  Google Scholar 

  30. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of serotonin reuptake inhibitors and their metabolites on Smephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481–5

    Article  PubMed  CAS  Google Scholar 

  31. Pies R. Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 1997; 42: 881

    PubMed  CAS  Google Scholar 

  32. Salokongas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175–80

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, University of Messina, Piazza XX Settembre 4, 98122, Messina, Italy

    Angela Avenoso, Gabriella Facciolà, Maria Gabriella Scordo &  Edoardo Spina

  2. Centers of Mental Health, Azienda USL 5, Messina, Italy

    Carmelo Gitto, Giuseppina Drago Ferrante, Aldo G. Madia &  Edoardo Spina

Authors
  1. Angela Avenoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriella Facciolà
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Gabriella Scordo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carmelo Gitto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giuseppina Drago Ferrante
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aldo G. Madia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Edoardo Spina
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Avenoso, A., Facciolà, G., Scordo, M.G. et al. No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia. Clin. Drug Investig. 16, 393–398 (1998). https://doi.org/10.2165/00044011-199816050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199816050-00007

Keywords

Search

Navigation